Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 17 | 2026 | 443 | 4.410 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 9 | 2026 | 77 | 2.810 |
Why?
|
| Immunotherapy | 4 | 2026 | 821 | 1.560 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2026 | 104 | 1.520 |
Why?
|
| Hematologic Diseases | 3 | 2017 | 77 | 1.010 |
Why?
|
| Cytarabine | 1 | 2026 | 218 | 0.910 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2026 | 2658 | 0.910 |
Why?
|
| Child | 23 | 2026 | 7680 | 0.870 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2026 | 246 | 0.860 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2019 | 977 | 0.830 |
Why?
|
| Central Nervous System Diseases | 1 | 2022 | 36 | 0.700 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2024 | 237 | 0.700 |
Why?
|
| Adolescent | 25 | 2026 | 10078 | 0.660 |
Why?
|
| Ploidies | 1 | 2019 | 39 | 0.580 |
Why?
|
| Asparaginase | 3 | 2026 | 38 | 0.550 |
Why?
|
| Child, Preschool | 12 | 2026 | 4000 | 0.540 |
Why?
|
| Injections, Spinal | 3 | 2026 | 49 | 0.530 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2017 | 66 | 0.480 |
Why?
|
| Young Adult | 21 | 2026 | 7504 | 0.470 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2018 | 262 | 0.460 |
Why?
|
| Immune System Diseases | 1 | 2015 | 25 | 0.440 |
Why?
|
| Antibodies, Bispecific | 2 | 2026 | 51 | 0.430 |
Why?
|
| Burkitt Lymphoma | 1 | 2014 | 32 | 0.410 |
Why?
|
| Humans | 42 | 2026 | 97894 | 0.400 |
Why?
|
| Antineoplastic Agents | 6 | 2026 | 2373 | 0.400 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 118 | 0.390 |
Why?
|
| Oxides | 2 | 2010 | 42 | 0.390 |
Why?
|
| Arsenicals | 2 | 2010 | 49 | 0.380 |
Why?
|
| Infant | 8 | 2026 | 3329 | 0.370 |
Why?
|
| Prognosis | 6 | 2026 | 4112 | 0.350 |
Why?
|
| Leukemia | 2 | 2025 | 308 | 0.340 |
Why?
|
| Folic Acid | 1 | 2011 | 68 | 0.330 |
Why?
|
| Neoplasms | 4 | 2025 | 3340 | 0.320 |
Why?
|
| Chromosome Aberrations | 2 | 2026 | 352 | 0.310 |
Why?
|
| Carnitine | 2 | 2021 | 14 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 1536 | 0.310 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2010 | 44 | 0.310 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2021 | 68 | 0.300 |
Why?
|
| Male | 24 | 2026 | 46996 | 0.290 |
Why?
|
| Communicable Diseases | 1 | 2010 | 74 | 0.290 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 209 | 0.290 |
Why?
|
| Female | 24 | 2026 | 51464 | 0.280 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 831 | 0.260 |
Why?
|
| Glucocorticoids | 1 | 2010 | 370 | 0.260 |
Why?
|
| Polyethylene Glycols | 2 | 2021 | 382 | 0.260 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 1764 | 0.250 |
Why?
|
| Remission Induction | 5 | 2019 | 754 | 0.240 |
Why?
|
| Hematology | 1 | 2026 | 37 | 0.240 |
Why?
|
| Molecular Targeted Therapy | 2 | 2026 | 321 | 0.230 |
Why?
|
| Treatment Outcome | 7 | 2026 | 9682 | 0.230 |
Why?
|
| Symptom Assessment | 1 | 2025 | 77 | 0.220 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2025 | 336 | 0.210 |
Why?
|
| Translocation, Genetic | 2 | 2016 | 245 | 0.200 |
Why?
|
| Hyperbilirubinemia | 2 | 2026 | 20 | 0.200 |
Why?
|
| Quality of Life | 2 | 2025 | 1891 | 0.190 |
Why?
|
| Palliative Care | 1 | 2025 | 289 | 0.190 |
Why?
|
| Disease-Free Survival | 3 | 2024 | 1193 | 0.190 |
Why?
|
| Leukemia, B-Cell | 1 | 2022 | 22 | 0.180 |
Why?
|
| Etoposide | 2 | 2019 | 207 | 0.170 |
Why?
|
| Research Design | 1 | 2025 | 650 | 0.170 |
Why?
|
| Methotrexate | 1 | 2022 | 227 | 0.170 |
Why?
|
| Cytogenetic Analysis | 2 | 2019 | 70 | 0.170 |
Why?
|
| Survivors | 2 | 2020 | 211 | 0.170 |
Why?
|
| Adult | 14 | 2026 | 29453 | 0.160 |
Why?
|
| Clinical Trials as Topic | 1 | 2025 | 1125 | 0.160 |
Why?
|
| Risk Factors | 4 | 2026 | 6224 | 0.160 |
Why?
|
| Retrospective Studies | 5 | 2022 | 10947 | 0.150 |
Why?
|
| Neoplasm, Residual | 2 | 2019 | 206 | 0.150 |
Why?
|
| Anthracyclines | 1 | 2019 | 31 | 0.150 |
Why?
|
| Infant, Newborn | 3 | 2019 | 2529 | 0.150 |
Why?
|
| Hematologic Neoplasms | 2 | 2016 | 383 | 0.140 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2019 | 849 | 0.140 |
Why?
|
| Recurrence | 1 | 2022 | 1254 | 0.140 |
Why?
|
| Postoperative Complications | 1 | 2010 | 2680 | 0.140 |
Why?
|
| Cancer Survivors | 1 | 2020 | 108 | 0.130 |
Why?
|
| Mediastinal Neoplasms | 1 | 2017 | 41 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2018 | 239 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2020 | 985 | 0.120 |
Why?
|
| Hodgkin Disease | 1 | 2017 | 144 | 0.120 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 155 | 0.120 |
Why?
|
| Prevalence | 2 | 2018 | 1384 | 0.120 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2016 | 6 | 0.120 |
Why?
|
| Induction Chemotherapy | 3 | 2026 | 151 | 0.120 |
Why?
|
| Blood Culture | 1 | 2016 | 13 | 0.120 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 37 | 0.120 |
Why?
|
| Bone Marrow Examination | 1 | 2015 | 40 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2017 | 325 | 0.110 |
Why?
|
| Philadelphia Chromosome | 1 | 2015 | 48 | 0.110 |
Why?
|
| Imatinib Mesylate | 1 | 2015 | 128 | 0.110 |
Why?
|
| Bacteremia | 1 | 2016 | 110 | 0.110 |
Why?
|
| Survival Rate | 4 | 2021 | 2040 | 0.110 |
Why?
|
| Prednisone | 2 | 2017 | 251 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 665 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2016 | 249 | 0.100 |
Why?
|
| U937 Cells | 2 | 2010 | 32 | 0.100 |
Why?
|
| Escherichia coli | 1 | 2016 | 572 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 304 | 0.090 |
Why?
|
| Leukemia, T-Cell | 1 | 2012 | 17 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 569 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 403 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2016 | 383 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2026 | 4023 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 1098 | 0.090 |
Why?
|
| Lymphoma, T-Cell | 1 | 2012 | 60 | 0.090 |
Why?
|
| Pediatrics | 1 | 2017 | 421 | 0.090 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2012 | 119 | 0.090 |
Why?
|
| United States | 5 | 2026 | 8184 | 0.090 |
Why?
|
| Transplantation, Homologous | 2 | 2012 | 1026 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2025 | 799 | 0.080 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 68 | 0.080 |
Why?
|
| Dithiothreitol | 1 | 2010 | 25 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2026 | 4798 | 0.080 |
Why?
|
| Acetylcysteine | 1 | 2010 | 73 | 0.070 |
Why?
|
| Biomarkers | 2 | 2022 | 2016 | 0.070 |
Why?
|
| Tretinoin | 1 | 2010 | 130 | 0.070 |
Why?
|
| Area Under Curve | 1 | 2010 | 340 | 0.070 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2022 | 111 | 0.070 |
Why?
|
| Protein Kinases | 1 | 2010 | 212 | 0.070 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2010 | 177 | 0.070 |
Why?
|
| Enzyme Activation | 1 | 2010 | 679 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 836 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2025 | 968 | 0.070 |
Why?
|
| Autophagy | 1 | 2010 | 177 | 0.070 |
Why?
|
| Dexamethasone | 1 | 2010 | 318 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 564 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2010 | 388 | 0.070 |
Why?
|
| Age Factors | 1 | 2012 | 1960 | 0.070 |
Why?
|
| ROC Curve | 1 | 2010 | 793 | 0.070 |
Why?
|
| Graft vs Host Disease | 1 | 2010 | 379 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2010 | 330 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 920 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2010 | 1145 | 0.060 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 525 | 0.060 |
Why?
|
| Sex Factors | 1 | 2010 | 1137 | 0.060 |
Why?
|
| Incidence | 2 | 2024 | 1776 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1778 | 0.060 |
Why?
|
| Disease Management | 1 | 2026 | 377 | 0.050 |
Why?
|
| Self Report | 1 | 2025 | 355 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 2892 | 0.050 |
Why?
|
| Thrombosis | 1 | 2026 | 318 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2010 | 1445 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2026 | 851 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2024 | 902 | 0.050 |
Why?
|
| Mucin-4 | 1 | 2022 | 7 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2026 | 682 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 2016 | 2007 | 0.040 |
Why?
|
| Base Sequence | 2 | 2016 | 2222 | 0.040 |
Why?
|
| Seizures | 1 | 2024 | 318 | 0.040 |
Why?
|
| Pediatric Obesity | 1 | 2021 | 38 | 0.040 |
Why?
|
| Acute Disease | 1 | 2022 | 857 | 0.040 |
Why?
|
| Sepsis | 1 | 2024 | 401 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 1527 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2018 | 94 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2022 | 1815 | 0.030 |
Why?
|
| Vinblastine | 1 | 2017 | 84 | 0.030 |
Why?
|
| Vincristine | 1 | 2017 | 102 | 0.030 |
Why?
|
| Bleomycin | 1 | 2017 | 102 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2017 | 104 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2016 | 15 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2017 | 284 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2017 | 285 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2017 | 174 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 1609 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1750 | 0.030 |
Why?
|
| Oncologists | 1 | 2016 | 43 | 0.030 |
Why?
|
| Marital Status | 1 | 2016 | 44 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1284 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2018 | 720 | 0.030 |
Why?
|
| Educational Status | 1 | 2016 | 205 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 271 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2016 | 386 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 3202 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 137 | 0.030 |
Why?
|
| Liver | 1 | 2018 | 1231 | 0.020 |
Why?
|
| Anxiety | 1 | 2016 | 370 | 0.020 |
Why?
|
| Genes, myc | 1 | 2012 | 38 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2012 | 50 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2012 | 83 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 2080 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 79 | 0.020 |
Why?
|
| World Health Organization | 1 | 2012 | 125 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2012 | 227 | 0.020 |
Why?
|
| Depression | 1 | 2016 | 616 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 5555 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 269 | 0.020 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2010 | 6 | 0.020 |
Why?
|
| Autophagy-Related Protein 7 | 1 | 2010 | 12 | 0.020 |
Why?
|
| Beclin-1 | 1 | 2010 | 15 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 2008 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 2037 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 201 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 186 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2010 | 212 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2010 | 2208 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2010 | 1285 | 0.010 |
Why?
|
| Aged | 1 | 2021 | 21702 | 0.010 |
Why?
|
| Mice | 1 | 2010 | 12707 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 28910 | 0.000 |
Why?
|